MELODY SANDS: Open Payments
NPI 1053397786 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$550 in 25 payments from 16 companies in 2025. Trend: 2023 $387 · 2024 $351 · 2025 $550
Food & beverage: $550
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 3 | $68 |
| ARRAY BIOPHARMA INC | 3 | $64 |
| Novartis Pharmaceuticals Corporation | 2 | $47 |
| AstraZeneca Pharmaceuticals LP | 2 | $47 |
| Janssen Biotech, Inc. | 2 | $47 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $45 |
| GlaxoSmithKline, LLC. | 2 | $32 |
| JAZZ PHARMACEUTICALS INC. | 1 | $26 |
| SERVIER PHARMACEUTICALS LLC | 1 | $25 |
| Astellas Pharma US Inc | 1 | $25 |
Products named: XALKORI, KISQALI, XTANDI, LYNPARZA, ZEPZELCA, TECVAYLI, Voranigo, Padcev.
Industry payments across IN — which companies pay providers there.
